253 related articles for article (PubMed ID: 9050852)
1. Site-specific mutagenesis reveals differences in the structural bases for tight binding of RNase inhibitor to angiogenin and RNase A.
Chen CZ; Shapiro R
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1761-6. PubMed ID: 9050852
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the interactions of human ribonuclease inhibitor with angiogenin and ribonuclease A by mutagenesis: importance of inhibitor residues inside versus outside the C-terminal "hot spot".
Shapiro R; Ruiz-Gutierrez M; Chen CZ
J Mol Biol; 2000 Sep; 302(2):497-519. PubMed ID: 10970748
[TBL] [Abstract][Full Text] [Related]
3. Superadditive and subadditive effects of "hot spot" mutations within the interfaces of placental ribonuclease inhibitor with angiogenin and ribonuclease A.
Chen CZ; Shapiro R
Biochemistry; 1999 Jul; 38(29):9273-85. PubMed ID: 10413501
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis of the complex of human RNase inhibitor and human eosinophil-derived neurotoxin (RNase 2).
Teufel DP; Kao RY; Acharya KR; Shapiro R
Biochemistry; 2003 Feb; 42(6):1451-9. PubMed ID: 12578357
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein.
Johnson RJ; McCoy JG; Bingman CA; Phillips GN; Raines RT
J Mol Biol; 2007 Apr; 368(2):434-49. PubMed ID: 17350650
[TBL] [Abstract][Full Text] [Related]
6. Molecular recognition of human angiogenin by placental ribonuclease inhibitor--an X-ray crystallographic study at 2.0 A resolution.
Papageorgiou AC; Shapiro R; Acharya KR
EMBO J; 1997 Sep; 16(17):5162-77. PubMed ID: 9311977
[TBL] [Abstract][Full Text] [Related]
7. Selective abolition of pancreatic RNase binding to its inhibitor protein.
Kumar K; Brady M; Shapiro R
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):53-8. PubMed ID: 14681553
[TBL] [Abstract][Full Text] [Related]
8. Molecular recognition of human eosinophil-derived neurotoxin (RNase 2) by placental ribonuclease inhibitor.
Iyer S; Holloway DE; Kumar K; Shapiro R; Acharya KR
J Mol Biol; 2005 Apr; 347(3):637-55. PubMed ID: 15755456
[TBL] [Abstract][Full Text] [Related]
9. Interaction of human pancreatic ribonuclease with human ribonuclease inhibitor. Generation of inhibitor-resistant cytotoxic variants.
Gaur D; Swaminathan S; Batra JK
J Biol Chem; 2001 Jul; 276(27):24978-84. PubMed ID: 11342552
[TBL] [Abstract][Full Text] [Related]
10. Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity.
Boix E; Wu Y; Vasandani VM; Saxena SK; Ardelt W; Ladner J; Youle RJ
J Mol Biol; 1996 Apr; 257(5):992-1007. PubMed ID: 8632481
[TBL] [Abstract][Full Text] [Related]
11. Toward rational design of ribonuclease inhibitors: high-resolution crystal structure of a ribonuclease A complex with a potent 3',5'-pyrophosphate-linked dinucleotide inhibitor.
Leonidas DD; Shapiro R; Irons LI; Russo N; Acharya KR
Biochemistry; 1999 Aug; 38(32):10287-97. PubMed ID: 10441122
[TBL] [Abstract][Full Text] [Related]
12. Kinetic characterization of two active mutants of placental ribonuclease inhibitor that lack internal repeats.
Lee FS; Vallee BL
Biochemistry; 1990 Jul; 29(28):6633-8. PubMed ID: 2397204
[TBL] [Abstract][Full Text] [Related]
13. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
14. Unexpected binding mode for 2'-phosphoadenosine-based nucleotide inhibitors in complex with human angiogenin revealed by heteronuclear NMR spectroscopy.
Tonan K; Xu P; Jenkins JL; Russo A; Shapiro R; Ni F
Biochemistry; 2003 Sep; 42(38):11137-49. PubMed ID: 14503864
[TBL] [Abstract][Full Text] [Related]
15. Tight-binding inhibition of angiogenin and ribonuclease A by placental ribonuclease inhibitor.
Lee FS; Shapiro R; Vallee BL
Biochemistry; 1989 Jan; 28(1):225-30. PubMed ID: 2706246
[TBL] [Abstract][Full Text] [Related]
16. Intraspecies regulation of ribonucleolytic activity.
Johnson RJ; Lavis LD; Raines RT
Biochemistry; 2007 Nov; 46(45):13131-40. PubMed ID: 17956129
[TBL] [Abstract][Full Text] [Related]
17. Structural features that determine the enzymatic potency and specificity of human angiogenin: threonine-80 and residues 58-70 and 116-123.
Shapiro R
Biochemistry; 1998 May; 37(19):6847-56. PubMed ID: 9578571
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of ribonuclease inhibition by ribonuclease inhibitor protein based on the crystal structure of its complex with ribonuclease A.
Kobe B; Deisenhofer J
J Mol Biol; 1996 Dec; 264(5):1028-43. PubMed ID: 9000628
[TBL] [Abstract][Full Text] [Related]
19. [Anti-oxidative effect of ribonuclease inhibitor by site-directed mutagenesis and expression in Pichia pastoris].
Wu Y; Zhao BC; Wang JH; Zhao P; Wu YN; Cui XY
Yi Chuan; 2005 Mar; 27(2):249-54. PubMed ID: 15843355
[TBL] [Abstract][Full Text] [Related]
20. Ribonuclease A variants with potent cytotoxic activity.
Leland PA; Schultz LW; Kim BM; Raines RT
Proc Natl Acad Sci U S A; 1998 Sep; 95(18):10407-12. PubMed ID: 9724716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
